Inspire Pharmaceuticals will move ahead with a blood-clotting drug after having a meeting with representatives of the Food and Drug Administration on July 29, the company said Wednesday.

The proposed drug is INS50589 Cardiovascular, It would be administered intravenously during heart bypass surgery.

Inspire said it would file an investigational new drug application with the FDA and launch a Phase I clinical trial this fall.